Key takeaways
- We found no published randomized trial that gave MOTS-c to people in our 21 November 2026 PubMed check.
- Trial NCT07505745 plans to compare MOTS-c with placebo in an estimated 120 adults and track adverse events, but no results were posted as of 21 November 2026.
- FDA says compounded MOTS-c “may pose significant risk for immunogenicity for certain routes of administration”, and that it has not identified any human exposure data.
- HHS cites a trial of a different molecule, so its account of that trial does not establish a safety profile for MOTS-c itself.
01Three sources answer different questions
If you searched “mots c side effects”, start by asking where a claimed reaction was recorded. These three sources answer different questions.
Clinical trials
What happened in each group? A trial can compare events between groups once results are available.
FDA reporting database
What was submitted to the agency? A submission is not a finding that the substance caused the event.
Published case reports
What happened to an individual patient? A case report can describe the sequence of events, but it cannot tell you how often an event occurs.
02What has been reported, and by whom?
| Source | What the record shows | What it cannot tell us |
|---|---|---|
| Hudson Biotech, ClinicalTrials.gov NCT07505745 | The 2026 randomized human trial plans to compare adverse events with placebo (estimated n=120). No results were posted as of 21 November 2026. | Which events occurred, how often, or whether one group had more events. |
| Published case reports | We found no published case report of an adverse event after MOTS-c was given to a person (PubMed, 21 November 2026). | Whether an event occurred but was never documented or published. |
The trial registry. In NCT07505745, one of the main questions is how often new or worsening health events occur after the study intervention begins. These are called treatment-emergent adverse events. The timing is what puts an event in that category. It does not mean the study substance caused it. This is a randomized human study design, not a set of human safety findings.
FDA’s adverse-event database. In its July 2026 briefing, FDA’s Office of Surveillance and Epidemiology said it searched the FDA Adverse Event Reporting System (FAERS) for MOTS-c through 28 February 2024, then again from 26 February 2024 through 9 March 2025. Neither search retrieved a report. That is FDA’s historical search, not a count through November 2026. FDA notes that compounders generally do not report adverse events to it, and that a report does not establish causation or show how often an event occurs.
The published literature. Measuring a peptide already in the body is different from giving it to participants. In a 2021 exercise study, Reynolds and colleagues measured naturally occurring MOTS-c in muscle and blood in 10 young men who cycled (T2, human measurements). The researchers did not give the peptide to those participants, so that part of the study tells us nothing about reactions to administered MOTS-c.
03Who is excluded from the registered trial?
The sponsor’s entry for NCT07505745 limits enrollment to adults aged 18–65 who meet its screening criteria. It does not accept healthy volunteers. Examples of the listed exclusions include:
- Pregnancy, breastfeeding, or plans for pregnancy during the study.
- Diabetes or recent use of glucose-lowering medication.
- Recent clinically significant cardiovascular disease or uncontrolled high blood pressure.
- Reduced kidney function below the trial’s cutoff, clinically significant liver disease, or liver enzyme levels above the trial’s limits.
- Known hypersensitivity to peptide therapeutics or to an ingredient in the study formulation.
These are enrollment rules, not findings of harm. Even once results are available, the trial will not directly answer how people it excluded would respond.
04What do FDA and HHS say?
FDA’s compounding safety page. FDA says compounded MOTS-c “may pose significant risk for immunogenicity for certain routes of administration”. Immunogenicity means the ability to trigger an immune response. FDA adds that such products “may have complexities with regard to peptide-related impurities and API characterization”. The entry remains under substances whose nominations were withdrawn. That is not a finding that the safety concern went away.
FDA’s July 2026 briefing. FDA staff did not identify clinical studies or human exposure data that would let them assess the safety of MOTS-c or MOTS-c acetate. Staff also did not identify nonclinical toxicity studies to inform that assessment. They flagged peptide clumping and impurities as possible contributors to an immune response, not as reactions observed in patients.
HHS’s October 2026 draft. The US Department of Health and Human Services names MOTS-c in its draft interim compounding enforcement policy. Appendix B says a randomized placebo-controlled trial of an unnamed analogue “reported no serious adverse events”. An analogue is a different molecule. That finding does not fill the human safety gap FDA identified for MOTS-c itself. The Federal Register notice of 30 October 2026 says the draft “is not binding on HHS or the public”.
05What we don’t know
We do not know whether MOTS-c causes reactions in people, which ones, how often, or what might emerge over longer follow-up. A lab report answers a separate question: what was tested in the sample from a particular batch.
Check that the batch identifier on the certificate of analysis (COA) matches the vial label.
Look for a named test and result for what the material is. A purity result alone does not establish identity.
A purity result does not tell you whether sterility or endotoxins were tested. Look for separate entries.
For examples of what each line can and cannot show, see how to read a COA. A batch report does not establish human safety.
If you think you’ve had a reaction to any product, seek medical care first. The reaction reporting guide explains where to submit a report.
This is a plain-English summary of research and public documents, dated 21 November 2026. It is not medical or legal advice.